Quintrio
Home

Stock overview

Ascendis Pharma A/S Ordinary Share

ASND

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Last trade $270.38
Day change -$1.35 (-0.50%)
Day range $260.94 – $281.35
Volume 356,617
Market cap $17.82B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for ASND.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ASND, quarterly periods
Line itemQ2 FY2019 Jun 30, 2019Q1 FY2019 Mar 31, 2019Q4 FY2018 Dec 31, 2018Q3 FY2018 Sep 30, 2018Q2 FY2018 Jun 30, 2018Q1 FY2018 Mar 31, 2018Q4 FY2017 Dec 31, 2017Q3 FY2017 Sep 30, 2017
Revenue$157K—$1.48M$40.79M$9.04M$8.2M$4.27M$27.19M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$157K—$1.48M$40.79M$9.04M$8.2M$4.27M$27.19M
Selling, general and administrative$10.15M$11.77M$10.82M$10.29M$11.29M$11.2M$8.82M$8.11M
Research and development$25.51M$22.02M$22.77M$23.48M$26.62M$25.73M$25.15M$24.03M
Total operating expenses$35.66M$33.79M$33.59M$33.77M$37.92M$36.94M$33.97M$32.15M
Operating income-$35.5M-$33.79M-$32.11M$7.02M-$28.88M-$28.74M-$29.7M-$4.96M
Interest expense————————
Income before taxes-$41.02M-$27.41M-$36.04M$5.38M-$43.74M-$20.95M-$27.43M-$653K
Income taxes$65K$2K$135K$133K$102K$127K-$170K$225K
Net income-$41.09M-$27.41M-$36.17M$5.24M-$43.85M-$21.08M-$27.26M-$878K
Net income attributable to common shareholders-$41.09M-$27.41M-$36.17M$5.24M-$43.85M-$21.08M-$27.26M-$878K
EBITDA-$33.52M-$31.8M-$32.11M$8.93M-$26.96M-$26.86M-$27.96M-$3.46M
Basic earnings per share-$0.07-$0.04-$0.06$0.01-$0.08-$0.04-$0.05—
Diluted earnings per share-$0.07-$0.04-$0.06$0.01-$0.08-$0.04-$0.05—

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel Growth

The global peptide therapeutics market is projected to grow from $112.20 billion in 2026 to $229.32 billion by 2036 at a 7.4% CAGR, driven by GLP-1 and incretin therapies, oral peptides, radioligands, and generic competition. Eli Lilly and Novo Nordisk lead the market with blockbuster incretin products, while emerging opportunities include oral macrocyclic peptides, radioligands, and generic semaglutide following patent expiry in major markets.

Zacks Investment Research

Bet on This New GLP-1 ETF to Gain Exposure to a Booming Market

REX Shares launched the REX Peptide ETF (PEPT), offering global exposure to peptide drug developers, manufacturers, and delivery platforms. The fund tracks the VettaFi Peptide Index and charges 65 bps in fees. With GLP-1 adoption expanding and the global incretin market projected to reach $200 billion by 2030, the peptide market is positioned for significant growth. PEPT competes with similar ETFs THNR and OZEM, which charge 59 bps each.

GlobeNewswire Inc.

TransCon® CNP (Navepegritid), einmal wöchentlich, erhält eine positive Bewertung des CHMP für die Behandlung von Achondroplasie bei Kindern

Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion for TransCon CNP (Navepegritide), a once-weekly treatment for achondroplasia in children aged 2+ years with open epiphyses. The European Commission is expected to make a final decision in Q4 2026, with market launch in Germany anticipated for Q1 2027 under the brand name YUVIWEL®. The drug was previously approved by the FDA in February 2026.

GlobeNewswire Inc.

TransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfant

Ascendis Pharma announced that the European Medicines Agency's CHMP committee issued a positive opinion recommending approval of TransCon CNP (navepegritide) for treating achondroplasia in children aged 2+ with open epiphyses. The European Commission's final decision is expected in Q4 2026, with commercial launch planned in Germany in Q1 2027 under the brand name YUVIWEL®.

Zacks Investment Research

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BridgeBio Pharma announced FDA acceptance of its regulatory filing for infigratinib, an oral drug to treat achondroplasia in children, with priority review and a decision expected by February 4, 2027. The drug demonstrated 2.1 cm/year greater height growth than placebo in Phase III trials. If approved, it would be the first oral therapy for achondroplasia, differentiating it from injectable competitors. BridgeBio also has two other near-term regulatory catalysts (BBP-418 and encaleret) that could diversify its revenue beyond its current marketed product Attruby.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.